{
    "title": "103_hr916",
    "content": "The \"Prescription Drug Prices Review Board Act of 1993\" establishes the Patented Medicine Prices Review Board within the Food and Drug Administration. The Board consists of 5 members appointed by the President, with Senate approval, who are experts in consumer advocacy, medicine, pharmacology, pharmacy, and prescription drug reimbursement. They must not have worked in the pharmaceutical industry in the year before appointment. Initial appointments must be made within 90 days of the Act's enactment, and each member serves a 5-year term, with exceptions for initial appointees. The Board consists of 5 members appointed by the President, with Senate approval, who are experts in consumer advocacy, medicine, pharmacology, pharmacy, and prescription drug reimbursement. Initial appointments are staggered for terms of 1 to 5 years. Vacancies are filled in the same manner as the original appointment, with replacements serving the remainder of the term. The Board consists of 5 members appointed by the President, with Senate approval, who are experts in consumer advocacy, medicine, pharmacology, pharmacy, and prescription drug reimbursement. Initial appointments are staggered for terms of 1 to 5 years. Members may serve after their term until a successor is in office. The initial meeting must be held within 90 days of the first appointments. The President designates a chairperson. Members are paid at a rate not exceeding the daily equivalent of the maximum annual rate of basic pay for grade GS-18 and receive travel expenses. The Board members are paid expenses, including per diem, in accordance with sections 5702 and 5703 of title 5, United States Code. The Board shall have a director appointed by the chairperson, who can also appoint additional staff. The director and staff must adhere to certain civil service laws and pay regulations. The Board is also responsible for regulating prescription drug pricing. The Board requires annual information from patentees of prescription drugs, including drug type, price, and production/marketing costs. They can decrease the length of a patent term for a prescription drug after notice. The Board can reduce the length of a patent term for a prescription drug if the patentee charges an excessive price for the drug. \"Excessive price\" is defined as the average price charged by the patentee for the drug in the preceding calendar year, adjusted for cost-of-living. The Board can reduce a patent term for a prescription drug if the patentee charges an excessive price, determined by considering various factors including average prices of similar drugs in the US. The Board can reduce a patent term for a prescription drug if the patentee charges an excessive price, considering factors like average prices of similar drugs in the US, costs of production and marketing, support from Federal agencies, tax benefits, compensation to officers, and other determinative factors. The Board can reduce a patent term for a prescription drug if the patentee charges an excessive price, and may recapture tax benefits if necessary. The Board can recapture tax benefits by increasing the patentee's tax under the Internal Revenue Code for each taxable year specified, based on the excessive price of prescription drugs sold. The Board can recapture tax benefits by increasing the patentee's tax under the Internal Revenue Code for each taxable year specified, based on the excessive price of prescription drugs sold. If the patentee charges an excessive price for a drug, the Board may manufacture and sell the drug. The Board may increase the length of a patent term for a prescription drug if the patentee has not charged an excessive price for the drug in the past 5 years and provides assurances of reasonable pricing during the extension. The Board can increase the term of a patent for a prescription drug, not exceeding 10 percent of the original term. Regulations must be developed within a year to implement the provisions. (g) Definitions.--For purposes of this section, the term \"patentee\" refers to the definition in section 100(d) of title 35, United States Code. A \"prescription drug\" is defined as a drug subject to regulation under section 503(b) of the Federal Food, Drug, and Cosmetic Act. SEC. 6. The Board will provide an annual report to Federal agencies on prescription drugs sold at excessive prices, including a list of such drugs, recommendations against dispensing them, and suggestions for alternative drugs. The chairperson of the Board has the authority to obtain official data from Federal agencies, use the United States mails, request administrative support services from the Administrator of General Services, and contract with government and private agencies for research and services necessary for the Board's duties. The Board has the authority to conduct investigations and issue subpoenas for witnesses and evidence related to potential violations of regulations under the Act. The Board has the authority to issue subpoenas for witnesses and evidence related to potential violations of regulations under the Act. If a person refuses to obey a subpoena, the Board can apply to a US district court for an order requiring compliance, with failure to obey punishable as civil contempt. Subpoenas and court orders are served according to federal rules. Service of process for court applications under paragraph (2) can be done in the judicial district where the person to be served resides or can be found. SEC. 8. Assistance for the Board requires reporting of subsidies paid to patentees by key agencies. SEC. 9. The Board must submit an annual report to Congress on its activities."
}